Balo concentric sclerosis (BCS), which was first described in 1928, is characterized by distinct alternating demyelinating rings. Brain MRI examinations of BCS reveal a distinct pattern of isointense and hyperintense rings that correspond to bands of preserved and destroyed myelin, respectively. MRI has also provided important information on the pathology of BCS; in particular, MRI results have indicated a gradient of decreasing perfusion from the center to the periphery of lesions, significant elevations of lactate at the periphery of lesions, and restricted diffusion at early stages of the disease. These findings suggest that hypoxic events may contribute to the pathogenesis of BCS.^[@R1]^

A previous histopathologic study revealed hypoxia-like tissue injury in active demyelinating lesions in BCS and the upregulation of ischemic tissue-preconditioning proteins such as hypoxia-inducible factor-1α (HIF-1α) at the periphery of BCS lesions.^[@R2]^ This report concluded that preserved myelin in BCS consisted of tissue-preconditioned oligodendrocytes that survived additional hypoxia-like injury.^[@R2]^ However, a hypothesis based on mathematical modeling of Liesegang ring formation suggests that the preconditioning theory alone may be insufficient to produce concentric rings with realistic diameters.^[@R3]^ Thus, researchers have speculated that both activating agents (currently unidentified) and protective agents such as tissue-preconditioning proteins might be necessary for the development of concentric rings in BCS; however, this theory has not been examined.

To address the aforementioned issues, we analyzed serial MRI and histopathologic findings from biopsied brain tissues obtained from a case of relapsing BCS.

METHODS {#s1}
=======

Neuropathologic analysis. {#s1-1}
-------------------------

Biopsied left parietal lesions were processed for paraffin-embedded to standard procedures. Immunohistochemical analysis and ultrastructural examination of the sample were performed as previously described.^[@R4]^

Standard protocol approvals, registrations, and patient consents. {#s1-2}
-----------------------------------------------------------------

This study was approved by the Tohoku University Human Research Ethics Committee with written informed consent.

RESULTS {#s2}
=======

Case. {#s2-1}
-----

A 45-year-old Japanese man was admitted to a local hospital for gradually progressive numbness and muscle weakness in his right arm. A brain MRI revealed concentric T2-hyperintense lesions with gadolinium-enhanced rings in the left parietal lobe. To exclude a brain tumor, an MRI-guided open brain biopsy was performed. After this biopsy, the patient received low-dose betamethasone, and his symptoms gradually subsided. One month later, he was discharged with only mild right arm weakness.

Five years later, the patient was rehospitalized because of speech difficulties and right arm weakness. In a neurologic examination, he exhibited nonfluent aphasia and moderate right hemiparesis. A brain MRI revealed a new T2 concentric lesion with several alternating hyperintense and isointense rings in the left frontal lobe ([figure 1](#F1){ref-type="fig"}). This lesion gradually expanded; its outermost hyperintense layer was visible in diffusion-weighted images. Apparent diffusion coefficient values were reduced only in the outermost layer of the diffusion-weighted image hyperintense lesion. Several gadolinium-enhanced rings were observed within the edge of the diffusion-restricted layer ([figure 1, A--L](#F1){ref-type="fig"}). CSF examination revealed a high myelin basic protein level (336 pg/mL), but the oligoclonal band was negative. After rigorous diagnostic workup to exclude diagnoses such as neoplasms, infections, and systemic autoimmune diseases, the patient was diagnosed with BCS. Although 3 courses of high-dose intravenous methylprednisolone and monthly intravenous cyclophosphamide therapy did not improve his symptom, after intravenous immunoglobulin (0.4 g/kg for 5 days × 2 courses), he became able to move his right limbs, and gadolinium enhancement in the brain lesion was attenuated. His symptoms improved further thereafter.

![Serial MRI findings for an expanding Balo concentric sclerosis lesion\
Images from the patient\'s second episode, obtained on December 9 (A, B, E, and H), December 13 (C, F, I, and K), and December 18 (D, G, J, and L) in 2015. (A) T2-weighted images (T2WIs) clearly depicted concentric lesions in the left frontal lobe. (B--L) Magnified images of the left frontal lobe depicted in (A) (rectangle). (B--D) T2WI revealed concentric patterns made by hyperintense and isointense rings in the lesion core, which was surrounded by regions with slightly elevated signal intensity. Both the core and peripheral regions of the lesion expanded in a concurrent manner (T2WI). (E--G) Gadolinium (Gd)-enhanced lesions were located only around the lesion core and were even detected in areas with uniform intensity in T2WI (post-Gd T1-weighted images \[T1-Gd\]). (H--J) Diffusion-weighted images (DWIs) exhibited high intensities in the peripheral regions beyond Gd-enhanced lesions. (K--L) Apparent diffusion coefficient (ADC) values gradually decreased from the center to the periphery of the lesion in a concentric manner (ADC map).](NEUROLOGY2015699538FF1){#F1}

Pathologic findings. {#s2-2}
--------------------

Tissue samples were obtained from the lesion in the left postcentral gyrus at onset ([figure 2, A--E](#F2){ref-type="fig"}). Subcortical white matter samples were spongy, suggesting brain edema. Many swollen eosinophilic astrocytes were present in the lesion, with a number of instances of perivascular cuffing. Concentric demyelinating lesions typical of Balo disease were observed; these lesions featured massive macrophage infiltration but preserved axons ([figure 2, F and I](#F2){ref-type="fig"}). Many glial fibrillary acidic protein--positive hypertrophic astrocytes were visible beyond the outer edges of the demyelinating layers ([figure 2, G and J](#F2){ref-type="fig"}). At the outer edge of the demyelinating lesion and in surrounding normal-appearing white matter, HIF-1α, a key factor in tissue preconditioning, was upregulated. HIF-1α was expressed mainly in glial cells; in particular, this protein was expressed by hypertrophic astrocytes ([figure 2, H and K](#F2){ref-type="fig"}). CC motif chemokine 2 (CCL2) and its receptor CC chemokine receptor type 2 (CCR2) were detected in active demyelinating lesions. CCL2 was expressed mainly in hypertrophic astrocytes, whereas CCR2 was detected in microglia and macrophages, which had infiltrated the demyelinating layers ([figure 2, L--N](#F2){ref-type="fig"}). Aquaporin 4 was also detectable in active demyelinating lesions. In demyelinating lesions, interleukin-1β (IL-1β) was found within foamy macrophages and, to a lesser degree, in hypertrophic astrocytes ([figure 2, O--P](#F2){ref-type="fig"}).

![MRI and histopathologic findings from the patient\'s initial episode\
(A--D) Prebiopsy MRI; (E) postbiopsy MRI. (A) T2-weighted image (T2WI) revealed concentric lesions in the left parietal white matter. (B--D) Magnified images of the parietal lobe depicted in (A) (rectangle). MRI findings and the presence of peripheral diffusion-weighted image (DWI) hyperintense lesions with gadolinium enhancements at lesion edges were similar to the results obtained during the patient\'s relapse (B, DWI; C, postgadolinium T1-weighted image; D, T2WI). (E) Postbiopsy MRI clearly indicated the resected area (red arrows) (T2WI). (F--P) histopathological findings for the biopsied brain (left parietal). (F--H, I--K, and L--N) Same areas, respectively. (F) Concentric demyelinating lesions were clearly recognizable by Klüver-Barrera myelin staining (scale bar = 500 μm). (G) Glial fibrillary acidic protein (GFAP)--positive hypertrophic astrocytes were observed beyond the edge of the demyelinating layers (GFAP \[brown\], scale bar = 500 μm). (H) Hypoxia-inducible factor-1α (HIF-1α) was upregulated around the outer edges of demyelinating lesions (HIF-1α \[brown\], scale bar = 500 μm). (I--K) High-magnification images of a selected area depicted in (F) (rectangle). Dotted lines mark the border between demyelinated and myelinated layers. (I) Myelin staining clearly revealed the boundary of demyelinated and myelinated regions (Klüver-Barrera myelin staining, scale bar = 200 μm). (J) Hypertrophic astrocytes were seen even in the nondemyelinating area. However, astrocytes were different morphologically in demyelinated and myelinated regions (balloon-shaped in the demyelinated area and star-shaped in the myelinated area; GFAP \[brown\], scale bar = 200 μm). (K) HIF-1α upregulation was particularly prominent in hypertrophic astrocytes (HIF-1α \[brown\], scale bar = 200 μm or 20 μm in inset of a single astrocyte). (L) Numerous activated macrophages had infiltrated the demyelinating lesions (myelin basic protein \[blue\]/CD68 \[brown\], scale bar = 150 μm). (M) CC motif chemokine 2 (CCL2) expression was evident in the cytoplasm of hypertrophic astrocytes (inset, scale bar = 20 μm), which were located mainly in peripheral demyelinating layers (CCL2 \[brown\], scale bar = 150). (N) Infiltrating cells (microglia and macrophages) in demyelinating layers expressed CC chemokine receptor type 2 (CCR2), especially in peripheral demyelinating layers (CCR2 \[brown\], scale bar = 150 μm). (O, P) Interleukin-1β (IL-1β) was not expressed in myelinated layers (O). However, in the demyelinating lesions, Il-1β expression was detected in macrophages and, to a lesser extent, in hypertrophic astrocytes (P) (IL-1β \[brown\], scale bar = 20 μm).](NEUROLOGY2015699538FF2){#F2}

DISCUSSION {#s3}
==========

The present study of BCS is unique in that a detailed pathologic study of developing concentric demyelinating lesions was conducted, we could compare MRI data with neuropathologic findings for the BCS lesions, and serial MRIs of expanding brain lesions of BCS were available at onset and relapse. Diffusion-restricted areas initially formed at lesion edges; subsequently, gadolinium-enhanced layers formed at the inner aspect of the initial lesions. These gadolinium-enhanced layers gradually lost their enhancement and became T2 hyperintense, which indicated that demyelination was occurring. These changes were accompanied by the outward emergence of new diffusion-restricted layers. The repetition of these processes led to the development of concentric rings characteristic of BCS. In addition, concentric demyelinating layers typical of BCS were histologically confirmed, and the expression of tissue preconditioning--related proteins was observed at the rim of periplaque regions, consistent with previously reported results.^[@R2]^ These findings indicated that a hypoxia-like event preceded demyelinating processes in BCS.

Those investigators hypothesized that this hypoxia-like tissue preconditioning would play a major role in causing concentric demyelination in BCS. Although this tissue preconditioning--based theory focuses on tissue protection mechanisms, the mechanisms by which BCS lesions expand have remained unclear. Moreover, they reported that oligodendrocytes were the main source of HIF-1α,^[@R2]^ whereas our findings indicated that astrocytes also abundantly expressed tissue preconditioning--related proteins in the outermost layer of concentric BCS lesions.

HIF-1α is a transcription factor that regulates cellular responses to hypoxia. Although HIF-1α expression in neurons prevents hypoxia-induced neuronal cell death, HIF-1α expression in astrocytes enhances neuronal cell death if both types of cells are cocultured.^[@R5]^ These HIF-1α--induced bystander effects of astrocytes could influence oligodendrocytes and may be associated with concentric lesion formation in BCS. The genes for both IL-1β and CCL2 carry multiple HIF-1 binding sites in their promoter regions and exhibit expression that is upregulated by hypoxia in astrocytes via HIF-1α expression.^[@R6],[@R7]^ IL-1β is a proinflammatory cytokine that may be associated with the progression of multiple sclerosis,^[@R8]^ and chronic IL-1β expression can induce reversible demyelination.^[@R9]^ In addition, elevated CCL2 expression has been detected in acute and chronic multiple sclerosis plaques, particularly in hypertrophic astrocytes.^[@R10]^ CCL2 is a chemotactic factor of T cells and macrophages, which exhibited massive infiltration into the BCS lesions examined in this study. We detected hypertrophic astrocytes that expressed IL-1β and CCL2 in lesions and CCR2-positive macrophages in demyelinating layers. Simply stated, HIF1-α--expressing astrocytes in tissue-preconditioned layers may secrete the 2 aforementioned proinflammatory cytokines and induce demyelination via IL-1β--induced tissue injury and the recruitment of pathogenic T cells and activated macrophages by CCL2, whereas HIF1-α--expressing oligodendrocytes in layers that have been subjected to tissue preconditioning may experience relatively little cellular damage. The MRI and pathologic findings in our case strongly suggest that hypoxia-like processes precede inflammation and demyelination in BCS and that tissue preconditioning and astrocyte-derived proinflammatory cytokines may contribute to producing a unique tissue-damage pattern that leads to the formation of concentric lesions. These pathologic findings should be confirmed in larger-scale analyses.
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